Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer

Journal of Clinical Oncology

Volumn 17, Issue 5, 1999, Pages 1625-1631

  Cortazar, Patricia ^a   Johnson, Bruce E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME;

EID: 0032896336     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.5.1625     Document Type: Review

References (41)

1. Salmon SE, Hamburger AW, Soehnlen B, et al: Quantitation of differential sensitivity of human-tumor stem cells to anticancer. N Engl J Med 298:1321-1327, 1978
2. Sanfilippo O, Daidone MG, Costa A, et al: Estimation of differential in vitro sensitivity of non-Hodgkin lymphomas to anticancer drugs. Eur J Cancer 17:217-226, 1981
3. Weisenthal LM, Marsden JA, Dill PL, et al: A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 43:749-757, 1983
4. Carmichael J, DeGraff WG, Gazdar AF, et al: Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of radiosensitivity. Cancer Res 47:943-946, 1987
5. Sondak VK, Korn EL, Kern DH: In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assay. Int J Cell Cloning 6:378-391, 1988
6. Bogden AE, Griffin W, Reich SD, et al: Predictive testing with the subrenal capsule assay. Cancer Treat Rev 11:113-124, 1984 (suppl A)
7. Poupon MF, Arvelo F, Goguel AF, et al: Response of small-cell lung cancer xenografts to chemotherapy: Multidrug resistance and direct clinical correlates. J Natl Cancer Inst 85:2023-2029, 1993
8. Fruehauf JP, Bosanquet AG: In vitro determination of drug response: A discussion of clinical applications, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology Updates (ed 4). Philadelphia, PA, JB Lippincott, 1993, pp 1-16
9. Markman M: Chemosensitivity and chemoresistance assays: Are they clinically relevant? J Cancer Res Clin Oncol 121:441-442, 1995
10. Markman M, Brown E: Tumor chemosensitivity and chemoresistance assay. Cancer 77:1020-1025, 1996
11. Gazdar AF, Steinberg SM, Russell EK, et al: Correlation of in vitro drug-sensitivity testing with response to chemotherapy and survival in extensive-stage small cell lung cancer: A prospective clinical trial. J Natl Cancer Inst 82:117-124, 1990
12. Ihde DC, Mulshine JL, Kramer BS, et al: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 12:2022-2034, 1994
13. Shaw GL, Gazdar AF, Phelps R, et al: Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. Cancer Res 53:5181-5187, 1993
14. Cortazar P, Gazdar AF, Woods E, et al: Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin Cancer Res 3:741-747, 1997
15. Mulrow C: The medical review article: State of the science. Ann Intern Med 106:485-488, 1987
16. Oxman AD, Cook DJ, Guyatt GH: Users' guides to the medical literature: VI. How to use an overview - Evidence-Based Medicine Working Group [see comments]. JAMA 272:1367-1371, 1994
17. Weed D: Methodologic guidelines for review papers. J Natl Cancer Inst 89:6-7, 1997
18. Alonso K: Human tumor stem cell assay: A prospective clinical trial. Cancer 54:2475-2479, 1984
19. Maenpaa JU, Heinonen E, Hinkka SM, et al: The subrenal capsule assay in selecting chemotherapy for ovarian cancer: A prospective randomized trial. Gynecol Oncol 57:294-298, 1995
20. Alberts DS, Chen HS, Salmon SE, et al: Chemotherapy of ovarian cancer directed by the human tumor stem cell assay. Cancer Chemother Pharmacol 6:279-285, 1981
21. Von Hoff DD, Clark GM, Stogdill BJ, et al: Prospective clinical trial of a human tumor cloning system. Cancer Res 43:1926-1931, 1983
22. Meyskens FLJ, Loescher L, Moon TE, et al: Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma. J Clin Oncol 2:1223-1228, 1984
23. Shaw GL, Gazdar AF, Phelps R, et al: Comparison of in vitro drug sensitivity testing results with response to chemotherapy and survival: Comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem 24:173-175, 1996
24. Von Hoff DD, Sandbach JF, Clark GM, et al: Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Ins 82:110-116, 1990
25. Von Hoff DD, Kronmal R, Salmon SE, et al: A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer 67:20-27, 1991
26. Yamaue H, Tanimura H, Tsunoda T et al: Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay. Eur J Cancer 27:1258-1263, 1991
27. Wilbur DW, Camacho ES, Hilliard DA, et al: Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill. Br J Cancer 65:27-32, 1992
28. Yamaue H, Tanimura H, Noguchi K, et al: Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay. Br J Cancer 66:794-799, 1992
29. Yamaue H, Tanimura H, Nakamori M, et al: Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay. Dis Colon Rectum 39:416-422, 1996
30. Hamburger A, Salmon S: Primary bioassay of human tumor stem cells. Science 197:461-463, 1977
31. Von Hoff DD: Send this patient's tumor for culture and sensitivity. N Engl J Med 308:154, 1983
32. Jense P, Holm B, Sorensen M, et al: In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: Preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabine. Br J Cancer 75:869-877, 1996
33. Tsai C, Chang K, Chen J, et al: Cytotoxic effects of gemcitabine containing regimens against human non-small cell lung cancer cell lines which express different levels of p185. Cancer Res 56:794-801, 1996
34. Lund B, Hansen O, Theilade K, et al: Phase II study of gemcitabine (2',2'-Difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86:1530-1533, 1994
35. Kohn EC, Sarosy G, Bicher A, et al: Dose intense taxol: High dose response rate in patients with platinum-resistance recurrent ovarian cancer. J Natl Cancer Inst 86:18-24, 1994
36. Seidman AD, Reichman BS, Crown JP, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
37. Seidman AD, Hudis CA, Raptis G, et al: Paclitaxel for breast cancer: The Memorial Sloan-Kettering Cancer Center experience. Oncology 11:20-28, 1997
38. Ravdin P, Burris HA, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
39. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
40. Fosella FV, Lee JS, Hong WK: Management strategies for recurrent non-small cell lung cancer. Semin Oncol 24:455-462, 1997
41. Fosella FV, Lee LS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995